06.30.21
Selexis SA and KBI Biopharma, both JSR Life Sciences companies, have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company focused on T cell redirecting cancer immunotherapies. The agreements leverage integrated services from Selexis and KBI as part of Immatics’ development of TCR Bispecifics, called TCER (T Cell Engaging Receptors), that simultaneously recruit, activate and stimulate the patient’s own T cells to detect, target and attack tumor cells.
Selexis will use its SUREtechnology Platform and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program.
“Immatics is pushing beyond the limitations of traditional antibody-based therapies by investigating targets beyond the cell surface to treat solid tumors,” said Dirk Lange, chief executive officer at Selexis and president and chief executive officer at KBI Biopharma. “The integrated workflow between Selexis’ SUREtechnology Platform and KBI’s development approach and cGMP Manufacturing is designed to rapidly advance complex, novel product candidates towards investigational new drug submissions, while also providing a strong foundation for subsequent late-stage development and commercialization.”
“Having delivered preclinical proof-of-concept for our TCR Bispecifics program IMA402 and having moved this program into GMP process development is a major achievement of Immatics,” said Sven Berger, CMC Project Leader at Immatics.
Selexis will use its SUREtechnology Platform and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program.
“Immatics is pushing beyond the limitations of traditional antibody-based therapies by investigating targets beyond the cell surface to treat solid tumors,” said Dirk Lange, chief executive officer at Selexis and president and chief executive officer at KBI Biopharma. “The integrated workflow between Selexis’ SUREtechnology Platform and KBI’s development approach and cGMP Manufacturing is designed to rapidly advance complex, novel product candidates towards investigational new drug submissions, while also providing a strong foundation for subsequent late-stage development and commercialization.”
“Having delivered preclinical proof-of-concept for our TCR Bispecifics program IMA402 and having moved this program into GMP process development is a major achievement of Immatics,” said Sven Berger, CMC Project Leader at Immatics.
